Belite Bio (Belite Bio) Total Assets : $101.15 Mil (As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Belite Bio Total Assets?

Belite Bio's Total Assets for the quarter that ended in Mar. 2024 was $101.15 Mil.

During the past 12 months, Belite Bio's average Total Assets Growth Rate was 154.00% per year. During the past 3 years, the average Total Assets Growth Rate was 275.00% per year.

During the past 4 years, Belite Bio's highest 3-Year average Total Assets Growth Rate was 275.00%. The lowest was 275.00%. And the median was 275.00%.

Total Assets is connected with ROA %. Belite Bio's annualized ROA % for the quarter that ended in Mar. 2024 was -32.16%. Total Assets is also linked to Revenue through Asset Turnover. Belite Bio's Asset Turnover for the quarter that ended in Mar. 2024 was 0.00.

Belite Bio Total Assets Historical Data

The historical data trend for Belite Bio's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Belite Bio Total Assets Chart

Belite Bio Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Total Assets

25.74

18.35

44.27

94.64

Belite Bio Quarterly Data
	Dec20	Jun21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Assets	Get a 7-Day Free Trial							39.82	60.70	57.60	94.64	101.15

Belite Bio Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Belite Bio's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Assets	=	Total Equity (A: Dec. 2023 )	+	Total Liabilities (A: Dec. 2023 )
	=	90.431	+	4.211
	=	94.64

Belite Bio's Total Assets for the quarter that ended in Mar. 2024 is calculated as

Total Assets	=	Total Equity (Q: Mar. 2024 )	+	Total Liabilities (Q: Mar. 2024 )
	=	96.47	+	4.677
	=	101.15

Belite Bio (NAS:BLTE) Total Assets Explanation

Total Assets is connected with ROA %.

Belite Bio's annualized ROA % for the quarter that ended in Mar. 2024 is

ROA %	=	Net Income (Q: Mar. 2024 )	/	( (Total Assets (Q: Dec. 2023 )	+	Total Assets (Q: Mar. 2024 ))	/ count )
	=	-31.484	/	( (94.642	+	101.147)	/ 2 )
	=	-31.484	/	97.8945
	=	-32.16 %

Note: The Net Income data used here is four times the quarterly (Mar. 2024) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Belite Bio's Asset Turnover for the quarter that ended in Mar. 2024 is

	Asset Turnover
=	Revenue (Q: Mar. 2024 )	/	( (Total Assets (Q: Dec. 2023 )	+	Total Assets (Q: Mar. 2024 ))	/ count )
=	0	/	( (94.642	+	101.147)	/ 2 )
=	0	/	97.8945
=	0.00

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Belite Bio Total Assets Related Terms

Thank you for viewing the detailed overview of Belite Bio's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Belite Bio (Belite Bio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Belite Bio Inc (NAS:BLTE) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

D01:Germany

Address

12750 High Bluff Drive, Suite 475, San Diego, CA, USA, 92130

Website

https://www.belitebio.com

Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively lead to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.